High tumor burden predicts poor response to enzalutamide in metastatic castration-resistant prostate cancer patients

Yu Ting Hsieh, Bing Juin Chiang, Chia Chang Wu, Chun Hou Liao, Chia Da Lin, Chung Hsin Chen

研究成果: 雜誌貢獻文章同行評審

摘要

To assess the predictive value of tumor burden on the biochemical response, and radiological response in Taiwanese metastatic castration-resistant prostate cancer (mCRPC) patients receiving enzalutamide. The mCRPC patients treated with enzalutamide were recruited from three hospitals. High tumor burden (HTB) was classified as metastases at either appendicular bone or visceral organ. Good prostate-specific antigen (PSA) response was defined as PSA reduction of 80%. In this cohort, there were 104 (54.2%) HTB patients and 88 (45.8%) with low tumor burden (LTB). Compared to LTB patients, fewer HTB patients had good PSA response (odds ratio: 0.43, range: 0.22–0.87, p = 0.019) and fewer radiological response (complete and partial remission) (odds ratio: 0.78, range: 0.36–1.68, p = 0.52) to enzalutamide. The disease control rate which also contained stable disease, was still lower in HTB (76.0%) than LTB group (92.9%, OR: 0.24, range: 0.07–0.77, p = 0.016) in the multivariable model. In addition, HTB patients had significantly shorter progression– free survival duration than did LTB patients (median: 8.3 vs. 21.6 months, log-rank test p = 0.003) in the univariable analysis. The tumor burden before the use of enzalutamide was associated with treatment outcomes. HTB reduced PSA response rate, radiological response rate and progres-sion-free survival duration.
原文英語
文章編號3966
期刊Cancers
13
發行號16
DOIs
出版狀態已發佈 - 8月 2 2021

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「High tumor burden predicts poor response to enzalutamide in metastatic castration-resistant prostate cancer patients」主題。共同形成了獨特的指紋。

引用此